+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Veterinary Vaccine Adjuvants Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4622444
  • Report
  • June 2019
  • Region: Global
  • 114 pages
  • Mordor Intelligence
until Mar 31st 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Bioveta as
  • Brenntag Biosector AS
  • Novavax
  • SPI Pharma
  • Zoetis
  • MORE
Market Overview

The Veterinary Vaccine Adjuvant market is anticipated to grow with a CAGR of around 6.4%, during the forecast period (2019-2024).

The growth of this market is owing to several factors, such as the rising use of adjuvants in the vaccine, an increase in livestock population and their associated diseases, and high incidence of infectious zoonotic diseases. For instance, according to the data published by the World Health Organization (WHO) 411 million livestock keepers belong to the rural poor population of 911 million people, from South Asia and the Sub-Saharan African region. Such close contact with animals is the major reason associated with the transfer of infectious zoonotic diseases. In addition, as per the Centers for Disease Control and Prevention (CDC), zoonotic diseases are very common and about three out of every four new or emerging infectious diseases in people are spread from animals, and more than six out of every 10 known infectious diseases in people are spread from animals. So, for the treatment of the aforementioned infectious zoonotic diseases, various types of vaccines are used. Thus, the growing burden of zoonotic diseases is among the major growth factor for the veterinary vaccine adjuvant market.

Scope of the Report

Vaccine adjuvants are substances that help to enhance the immune response of vaccine. The adjuvants can be broadly classified into two types, the first one is vaccine delivery systems and the second one is immunostimulatory adjuvants.

Key Market Trends

Alum and Calcium Salts is Expected to Hold the Largest Share in the Market Segmentation by Type

Aluminum-based adjuvants have been used most commonly for vaccine preparations for more than 80 years. They include aluminum hydroxide and phosphate adjuvants, as well as calcium phosphate adjuvants. In addition, the safety of these adjuvants is excellent, and there are very fewer side effects. But there are some allergic reactions and granulomas occasionally in a few cases. And moreover, the recent developments, such as the use of aluminum oxyhydroxide nanoparticles in the formulation of vaccine adjuvants, are more effective in the prevention of infectious diseases and treatment of various diseases.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. This is due to the rising adoption of companion animals, increasing pet healthcare insurance, and improved veterinary healthcare infrastructure. In the North America region, the United States holds the largest market share. And with the rising trends of zoonotic diseases in the United States, the associated use of the veterinary vaccine is also increasing. Hence, it is expected to propel the growth of the veterinary vaccine adjuvants market over the forecast period.

Competitive Landscape

The Veterinary Vaccine Adjuvant market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising prevalence of infectious diseases in the animals, few other smaller players are expected to enter into the market in the coming years. Some of the major players of the market are SEPPIC, SPI Pharma, Brenntag Biosector A/S, Bioveta AS, and Zoetis are among others.
Note: Product cover images may vary from those shown
2 of 4


  • Bioveta as
  • Brenntag Biosector AS
  • Novavax
  • SPI Pharma
  • Zoetis
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Use of Adjuvants in Vaccine
4.2.2 Increase in Livestock Population and their Associated Diseases
4.2.3 High Incidence of Infectious Zoonotic Diseases
4.3 Market Restraints
4.3.1 High Toxicity and Side Effects of Adjuvants
4.3.2 Stringent Regulatory Environment and Time-consuming Approvals
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type
5.1.1 Alum and Calcium Salts
5.1.2 Oil Emulsion Adjuvants
5.1.3 Liposomes and Archaeosomes
5.1.4 Nanoparticles and Microparticles
5.1.5 Other Types
5.2 By Application
5.2.1 Research Application
5.2.2 Commercial Application
5.3 By Route of Administration
5.3.1 Oral
5.3.2 Subcutaneous
5.3.3 Intramuscular
5.3.4 Other Routes of Administration
5.4 By Animal Type
5.4.1 Livestock
5.4.2 Companion Animal
5.4.3 Other Animal Types
5.5 Geography
5.5.1 North America US Canada Mexico
5.5.2 Europe Germany UK France Italy Spain Rest of Europe
5.5.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.5.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.5.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Bioveta as
6.1.2 Brenntag Biosector AS
6.1.3 Novavax
6.1.4 Phibro Animal Health Corporation
6.1.5 SEPPIC
6.1.6 SPI Pharma
6.1.7 Zoetis

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Bioveta as
  • Brenntag Biosector AS
  • Novavax
  • Phibro Animal Health Corporation
  • SPI Pharma
  • Zoetis
Note: Product cover images may vary from those shown